• Health & Medicine

Immunotherapy for triple negative breast cancer approved for NHS in England 

Atezolizumab used in combination with nab-paclitaxel is the first immunotherapy available for triple negative breast cancer. Atezolizumab used in combination with nab-paclitaxel is the first immunotherapy available for triple negative breast cancer.

26 May 2020

• Health & Medicine

Breast and ovarian cancer drug effective in advanced prostate cancer

A targeted cancer drug, already licensed for treating some breast and ovarian cancers, is found to be effective for some men with advanced prostate cancer. A targeted cancer drug, already licensed for treating some breast and ovarian cancers, is found to be effective for some men with advanced prostate cancer.

1 May 2020

• Health & Medicine
• Policy & Insight

How coronavirus is impacting cancer services in the UK

Cancer services have been severely disrupted across the UK, from screening to treatment and care. Cancer services have been severely disrupted across the UK, from screening to treatment and care.

21 April 2020

• Health & Medicine

Three new treatment options approved for NHS use in Scotland

The Scottish Medicines Consortium (SMC) has accepted 3 new cancer treatments for NHS use in Scotland The Scottish Medicines Consortium (SMC) has accepted 3 new cancer treatments for NHS use in Scotland

26 March 2020

• Health & Medicine

Non-Hodgkin lymphoma treatment gets an initial ‘no’ for NHS use in England

A new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma has not been recommended for NHS use in England.  A new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma has not been recommended for NHS use in England. 

11 March 2020

• Health & Medicine

‘Chemotherapy-free’ treatment for lymphoma made available for NHS use in England

New ‘chemotherapy-free’ treatment for follicular lymphoma approved for NHS use in England. New ‘chemotherapy-free’ treatment for follicular lymphoma approved for NHS use in England.

28 February 2020

• Health & Medicine

Kidney cancer drug gets initial ‘no’ for the NHS in England

A new kidney cancer drug combination of pembrolizumab with axitinib gets an initial no for the NHS in England A new kidney cancer drug combination of pembrolizumab with axitinib gets an initial no for the NHS in England

17 February 2020

• Health & Medicine

Two skin cancer treatments get the green light for NHS Scotland

An immunotherapy and a targeted cancer drug were among the latest batch of NHS approvals from the Scottish Medicines Consortium (SMC).  An immunotherapy and a targeted cancer drug were among the latest batch of NHS approvals from the Scottish Medicines Consortium (SMC). 

12 February 2020

• Health & Medicine

Targeted lung cancer treatment gets initial ‘no’ for NHS in England

Adults in England with advanced lung cancer will not have access to a new targeted cancer drug, lorlatinib (Lorviqua).  Adults in England with advanced lung cancer will not have access to a new targeted cancer drug, lorlatinib (Lorviqua). 

4 February 2020

• Health & Medicine

Leukaemia and head and neck cancer drugs not approved for NHS use in England

Leukaemia and head and neck cancer drugs have not been recommended for NHS use in England. Leukaemia and head and neck cancer drugs have not been recommended for NHS use in England.

23 January 2020

• Health & Medicine

Hormone therapy now available for newly diagnosed prostate cancer in Scotland 

A hormone therapy has been approved for NHS use in Scotland for some people with newly diagnosed, advanced prostate cancer for the first time.   A hormone therapy has been approved for NHS use in Scotland for some people with newly diagnosed, advanced prostate cancer for the first time.  

20 January 2020

• Health & Medicine

New breed of targeted cancer drug gets initial ‘no’ for NHS in England  

A targeted drug, larotrectinib (Vitrakvi), will not be made an option for adults and children whose tumours test positive for a specific genetic change. A targeted drug, larotrectinib (Vitrakvi), will not be made an option for adults and children whose tumours test positive for a specific genetic change.

15 January 2020